ABSTRACT
The cross-linking enzyme, Transglutaminase 2 (TGase 2), contributes to physiological homeostasis and plays a role in cell death and survival. We previously showed that down-regulation of TGase 2 by cystamine or synthetic peptide R2 promotes apoptosis in drug-resistant cancer cells by restoring the level of I-κBα, leading to inactivation of NF-κB. To better define the action of TGase 2, its expression was blocked by small interfering RNA. This interference rendered, the doxorubicin-resistant breast cancer cells, highly susceptible to doxorubicin-induced apoptosis. This susceptibility, was associated with decreased levels of the cell-survival factors BCl 2 and BCL XL whereas the level of BAX remained un-changed. Together, the findings support the view that TGase 2 leads to drug-resistance by up-regulating the level of survival factors via NF-κB activation.
INTRODUCTION
Drug-resistance frequently occurs in response to the use of alkaloids and antibiotics, including anthracyclines such as doxorubicin and daunomycin, vinca alkaloids, actinomycin D, etoposide and paclitaxel, likely due to NF-κB activation (1-3). NF-κB activation enhances resistance and suppresses apoptosis due to chemotherapeutic agents and for this reason this activation might be important in the development of drug resistence in cancers (2) (3) (4) . The activation of NF-κB occurs in response to many factors including Transglutaminase 2 (TGase 2) (5). TGase 2 cross-links protein bound-glutamine andlysine, and leads to the formation of covalent iso-peptide bonds (6) . A unqiue feature of TGase 2 is that activation of the downstream transcription factor(s) such as NF-κB, does not require ATP but rather, calcium. Expression of TGase 2 is elevated in drug-resistant cancer cell lines (7, 8) .
Interestingly, this drug-resistance to chemotherapeutic drugs can be counteracted by the inhibition TGase 2. Here we tested the hypothesis that this inhibiton might be mediated by virtue of changes in expression of factors that have an anti-apoptotic effect (7).
MATERIALS AND METHODS

Antibodies and reagents
The anti-I-κB antibody was from Cell Signaling Technologies (Beverly, MA, USA), the anti-TGase 2 antibody from NeoMarkers (clone CUB 7402; Fremont, USA), and anti-β-actin from Abcam (Headquarters: Cambridge, UK). The anti-Bax, anti-Bcl 2 and anti-Bcl xL antibodies were acquired from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Lipofectamine 2000 and Lipofectamine RNAiMAX transfection regents from Invitrogen (Carlsbad, CA, USA), Lipofectamine RNAiMAX with Stealth Negative control from invitrogen (Carlsbad, CA, USA), and propidium iodide solution and RNAase A from Sigma (St Louis, MO, USA).
Cell culture and sub-cellular preparation
The human breast cancer cell lines included MDA-468 (doxorubicin sensitive) and MDA-231 (doxorubicin resistant). These cell lines were obtained from the American Type Culture Collection. Cells were grown in RPMI (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 1mM sodium pyruvate (Gibco-BRL, Grand Island, NY, USA), and 100 U/ml penicillin-streptomycin (Gibco-BRL, Grand Island, NY, USA), and maintained in a humidified atmosphere of 5% CO 2 at 37°C. Cytoplasmic cellular fractions were prepared using a CelLytic TM NuCLEAR TM Extraction Kit (Sigma, St Louis, MO, USA).
Transient transfection
For the secreted alkaline phosphatase (SEAP) reporter assay, transient transfection of a reporter plasmid carrying the NF-κB promoter (pNF-κB-SEAP; BD Bioscience, Mountain View, CA, USA) and pGAL plasmid were co-transfected using 3 µl of Lipofectamine 2000 (Invitrogen), according to the manufacturer's instruction. The data represent the average and standard deviation (SD) of three independent experiments.
NF-κB activity assay
NF-κB activity was measured using the SEAP reporter system 3 (BD Bioscience, Mountain View, CA, USA). TGase 2-specific siRNA-transfected cells were cotransfected with pNF-κB-SEAP and pGAL, then subjected to 24 and 48 h post-transfection. Then, the culture media were collected for an SEAP assay, and the cells were harvested for a β-galactosidase assay. The SEAP assay was performed according to the manufacturer (BD Bioscience, Mountain View, CA, USA) instruction. The data represent the average and SD of three independent experiments.
TGase 2 gene silencing by small interfering RNA
A small interfering RNA (siRNA) duplex targeting human TGase 2, 5′-AAGAGCGAGAUGAUCUGGAAC-3′ (Invitrogen) was introduced into the cells using Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer's instruction. 48 h after transfection, the cells were harvested, and a cytosolic fraction was prepared in order to analyze the level of TGase 2 and I-κBα by Western blotting. Cells incubated with Lipofectamine RNAiMAX and Stealth Negative control (Invitrogen) were employed as the negative control. The data represent the average and SD of three independent experiments.
Western blotting
Western blotting has performed followed by the previously established method. The primary antibodies used in these studies were anti-I-κBα, anti-TGase 2, anti-β-actin, anti-Bax and anti-Bcl 2 .
TGase activity assay
A modified TGase activity assay was used, which measured the incorporation of (1,4-14 C)putrescine into succinylated casein. 
Apoptosis assay
For the cell cycle analysis, TGase 2 siRNAtransfected cells were seeded and exposed to doxorubicin for 48 h. Then, they were collected, washed with PBS, and fixed with 100% ethanol at 4°C for 24 h. Fixed cells were washed three times and incubated for 30 min with propidium iodide solution (Sigma, St Louis, MO, USA) containing RNAase A (Sigma, St Louis, MO, USA). Cells were then subjected to cell cycle analysis in order to determine the DNA content by flow cytometry (FacsCalibur, Becton-Dickinson). The data are provided as percent hypoploidy (i.e. the percentage of cells with a sub-G1 DNA content), which reflects the percentages of apoptotic cells with fragmented genomic DNA. The analysis of annexin V binding was carried out using an Annexin V-FITC Apoptosis Detection Kit (BD Biosciences, Mountain View, CA, USA) according to the manufacturer's instructions. Cells were collected, washed twice with cold PBS, and centrifuged at 1500 rpm for 5 min. Cells were then resuspended in 1x binding buffer at a concentration of 1X10 6 cells per ml, 100 µl of the solution was transferred to a 5 ml culture tube, and 5 µl of annexin V-FITC and 5 µl of PI were added. The cells were gently vortexed and incubated for 15 min at room temperature in the dark. Finally, 400 µl of 1x binding buffer was added to each tube, and the samples were analyzed by FACScan flow cytometry. For each sample, 10,000 ungated events were acquired. PI (-)/annexin (+) cells represent the early apoptotic populations
RESULT AND DISCUSSION
TGase 2 expression and enzyme activity in two breast cancer cell lines
Previously, we reported that the expression of TGase 2 is elevated in drug-resistant and not drug sensitive breast cancer cell lines (7) . The level of TGase 2 is up to 20-fold higher in the drug-resistant MDA231 cell line as compared with the drugsensitive MDA468 cell line ( Figure 1A) . Also, the activity of the TGase 2 enzyme is up to 22-fold higher in the drug-resistant MDA231 cell line as compared with the drug-sensitive MDA468 cell line ( Figure 1B) . 
NF-κB activity is decreased by TGase 2 gene silencing
To test whether TGase 2 gene silencing affects NF-κB activity in the drug-resistant MDA231 cell line, Western blotting and an NF-κB reporter assay were peformed. This silencing led to decreased level of TGase 2 expression (about 7-fold) and TGase activity (5-fold decreased ) (Figure 2A and 2B) . The Western blot analysis of I-κBα showed a dramatic, dose-dependent increase of I-κBα by TGase 2 siRNA treatment (Figure 2A ).
Transfection with Stealth Negative control RNA, or the non-transfected MDA231 celIs did not affect the levels of TGase 2 or I-κBα (data not shown). We examined whether TGase 2 gene silencing suppresses NF-κB activity in drugresistant breast cancer cells. The reporter gene activity of the NF-κB promoter in the MDA231 cells was decreased by about 3-fold by treatment with 200 nM of TGase 2 siRNA ( Figure 2C ). TGase 2 gene silencing reversed the NF-κB activity via restoration of the level of I-κBα. These data concord with the previous finding that cystamine and R2 peptide reverses NF-κB activity via restoration of the I-κBα level in MCF7/Dox cells (7).
TGase 2 gene silencing reduces the level of nuclear NF-κB in the drug-resistant MDA231 cell line
To test whether TGase 2 gene silencing reduces nuclear translocation of NF-kB, immunocytochemical staining of p65 was performed after TGase 2 siRNA treatment for 48 hr (Figure 3 ). This treatment inhibited TGase 2 expression in MDA231 cell line ( Figure 3A) . Treatment of MDA231 cells with Stealth Negative control RNA, led to peripheral nuclear staining of p65 whereas cells transfected with TGase 2-targeted siRNA showed very little nuclear staining of p65 and showed mostly staining in the cytoplasm ( Figure 3B ).
TGase 2 gene silencing increases sensitivity to doxorubicin-induced apoptosis in MDA231 cells
To determine whether TGase 2 gene silencing promotes chemosensitivity in the drug-resistant MDA231 cell line, we performed a cell viability MTT assay usingt doxorubicin (Figure 4) . We first determined the IC 50 value for the doxorubicin in drug-resistant MDA231 cell line. The cells were treated with various concentrations of doxorubicin, and the cell viability was determined by MTT assay after 48 hr of treatment. Treatment with 5 and 10 µM doxorubicin led to apoptosis in ~50% of the drug-resistant MDA231 cells had ( Figure 4A ). Ablation of TGase 2 expression did not affect the tendency to apoptosis ( Figure  4B ). These data are consistent with reports in TGase 2 knock-out mice, that do not show any change in apoptotic progress (27, 28) . To test whether TGase 2 gene silencing affects cell survivability after treatment with doxorubicine, MDA231 cells were treated with 5 or 10 µM of doxorubicin together with TGase 2 siRNA ( Figure 4C ). The cell viability 48 hr after treatment, showed that drug sensitivity was significantly increased, by about 2-fold ( Figure 4C ). The number of apoptotic cells was quantitated by flow cytometry using propidium iodide (PI) staining after transfection of cells with TGase 2 siRNA ( Figure 5 ). The PI-stained cells were concentrated on the sub-G 1 cellular DNA fraction. Treatment of doxorubicin and transfection with TGase 2 siRNA resulted in an approximately 1.5-fold increase in the number of apoptotic DNA in the sub-G 1 fraction compared with the cells treated with the negative control siRNA ( Figure 5A) . A series of experiments suggested that TGase 2 siRNA sensitized the doxorubicin-resistant MDA231 breast cancer cells to the doxorubicin. The early-apoptotic rate was assessed after treatment of cells with 10 µM doxorubicin and transfection with TGase 2 siRNA by double-staining with Annexin V-FITC and PI using flow cytometry . As shown in Figures  5B and 5C , the early apoptosis rate was increased by the TGase 2 siRNA treatment, compared with control cells transfected with control siRNAs.
TGase 2 gene silencing reduces the levels of survival factors BCl 2 and BCl XL
To investigate the mechanism by which TGase 2 gene silencing increases sensitivity to drug-induced apoptosis, a series of Western blotting against apoptosis factors was performed with or without TGase 2 siRNA treatment in MDA231 cells ( Figure 6 ). The results showed that the expression of Bcl 2 and Bcl xL was down-regulated dose-dependently by TGase 2 gene silencing, whereas the expression level of Bax remain un-changed.
DISCUSSION
In this study, increased expression of the survival factors BCl 2 and BCl XL was observed in drug-resistant breast cancer cell lines. Furthermore, the expression level of these factors was decreased by TGase 2 gene silencing After 48 h incubation, the relative cell numbers were determined by MTT assay, as described in Materials and methods. C. After siRNA treatment for 48 h, the cells were exposed to doxorubicin (5 and 10 µM) for another 48 h. After incubation, the relative cell numbers were determined by MTT assay. suggested that TGase 2 over-expression causes constitutive activation of the FAK and PI3K/Akt system, which can result in increased levels of survival factors (11) . Interestingly, Akt signaling also activates NF-κB via IKK activation, which might result in increased BCl 2 expression (12). This observation is in concordance with recent findings that increased TGase 2 expression induces NF-κB activation in various cell lines including microglia (5), neuroblastoma (5), human kidney (13), breast cancer (7), astrocyte (14) , and melanoma (15) . (16) (17) (18) . Contrarily, many reports also found evidence of TGase 2 involvement in apoptosis; specifically, whereas its over-expression triggered cells to die, its inhibition by gene silencing rendered the cells resistant to apoptosis (19) (20) (21) (22) (23) (24) (25) (26) . However, there is the discrepancy that, in other studies, Tgm-/-mice showed no statistically significant differences, compared with Tgm2+/+ mice, for any of the measured parameters (27) (28) . Indeed, the cells were triggered to die without TGase 2. The lack of TGase 2 activity in Tgm-/-mice is only associated with smaller thymuses and less TUNEL positivity, owing to decreased cell death or an increased rate of dead cell clearance (28) . TGase 2 over-expression enhances the response to apoptosis signaling (29) , but the specific mechanism of TGase 2 in apoptosis remains to be elucidated. TGase 2 certainly plays a role both in cell death and survival that can contribute to homeostasis (24) .
Although we demonstrated that via TGase 2 overexpression, cell survivability increases concomitantly with constitutive activation of NF-κB, there are other possible explanations. TGase 2 can increase cell survivability as a G protein. According to Aeschlimann et al., TGase 2 can promote cell adhesion by regulating and being regulated by phospholipase C through binding to it with the non-transamidating GTP form of the enzyme (30) (31) . This pathway involves protein kinase C, Rho and focal adhesion kinase, but the mechanism is independent of the transamidation of TGase 2. The Szondy group has also shown that TGase 2, as a G protein, inhibited Fas-mediated cell death (32) . As a cross-linking enzyme, TGase 2 prolongs cell survivability by polyamine modification of Rb. TGase 2 protects Rb from caspase-induced degradation in a transamidation-dependent manner (17) , suggesting that transamidation of Rb by TGase 2 is necessary for its ability to inhibit apoptosis. We also demonstrated that drugresistant cancer cells with high NF-κB activity turned into drug-sensitive cells as a result of treatment with either of the TGase inhibitors cystamine or synthetic peptide R2 (7).
It remains to be clarified whether increased cell survivability as a result of increased TGase 2 expression is dependent on transamidation or G protein; still, the reduced expression of TGase 2 using siRNA dramatically decreased the levels of the cell-survival factors BCl 2 and BCL XL .
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